The global market for Mpox Therapeutics was valued at US$90.0 Million in 2025 and is projected to reach US$148.6 Million by 2032, growing at a CAGR of 7.4% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.
Healthcare providers rely on protocols that guide initiation and dosing of antivirals based on clinical severity. Intravenous or oral regimens are selected according to patient condition and drug availability. Treatment also involves monitoring for side effects and adjusting therapy in response to kidney or liver function. In resource-limited settings, timely access to antiviral stockpiles and clear treatment guidelines remain critical for effective patient management.
Clinical trials focus on assessing safety, dosing, and efficacy across diverse patient groups. Special attention is given to understanding drug impacts in vulnerable populations such as children, elderly people, and immunosuppressed individuals. Drug developers are also exploring combination therapies that pair antivirals with immune modulators to enhance outcomes. Regulatory agencies have begun granting emergency use authorizations for some treatments, enabling broader access while formal approvals progress.
Pharmaceutical companies are also scaling production capacities and restructuring supply chains to meet increasing demand. They are exploring flexible manufacturing processes that can quickly adapt volumes as needed. Distribution systems now include temperature-controlled transport, real-time tracking, and regional hubs to reach remote areas efficiently. Such logistics enhancements are vital to avoid stockouts and ensure treatment availability during epidemic peaks.
Global Mpox Therapeutics Market - Key Trends & Drivers Summarized
Why Are Antiviral Treatments Central in Mpox Care?
Antiviral treatments are crucial in managing severe mpox cases and limiting complications. These treatments help reduce viral replication once infection is confirmed. Currently available options include antiviral drugs originally developed for related viruses. Access to effective therapeutics enables clinicians to treat high-risk patients, such as immunocompromised individuals, pregnant persons, and children. Early intervention with antiviral therapy improves patient outcomes and reduces the risk of severe disease progression.Healthcare providers rely on protocols that guide initiation and dosing of antivirals based on clinical severity. Intravenous or oral regimens are selected according to patient condition and drug availability. Treatment also involves monitoring for side effects and adjusting therapy in response to kidney or liver function. In resource-limited settings, timely access to antiviral stockpiles and clear treatment guidelines remain critical for effective patient management.
What New Treatments Are Emerging or Under Study?
Research into novel therapies has intensified due to rising mpox incidence and growing public health interest. Experimental drugs targeting viral replication mechanisms are in various stages of clinical development. Some candidates offer broader antiviral activity. Others are designed specifically for mpox. Research efforts also include evaluating monoclonal antibodies aimed at neutralizing the virus. These treatments may offer passive immunity and support for severe or refractory cases.Clinical trials focus on assessing safety, dosing, and efficacy across diverse patient groups. Special attention is given to understanding drug impacts in vulnerable populations such as children, elderly people, and immunosuppressed individuals. Drug developers are also exploring combination therapies that pair antivirals with immune modulators to enhance outcomes. Regulatory agencies have begun granting emergency use authorizations for some treatments, enabling broader access while formal approvals progress.
How Are Access and Distribution Evolving?
Mpox therapeutics are being distributed through public health channels, emergency stockpiles, and international aid programs. Partnerships between government agencies, non-governmental organizations, and manufacturers facilitate medicine allocation in low-resource regions. Programs often include training for clinicians to identify eligible patients, manage treatment regimens, and monitor for adverse events. This coordinated approach helps ensure equitable treatment access in outbreak zones.Pharmaceutical companies are also scaling production capacities and restructuring supply chains to meet increasing demand. They are exploring flexible manufacturing processes that can quickly adapt volumes as needed. Distribution systems now include temperature-controlled transport, real-time tracking, and regional hubs to reach remote areas efficiently. Such logistics enhancements are vital to avoid stockouts and ensure treatment availability during epidemic peaks.
Growth in the Mpox Therapeutics Market Is Driven by Several Factors
Growth in the mpox therapeutics market is driven by several factors. Rising global mpox cases have increased demand for effective treatments. Emergency authorizations and approvals of new antiviral agents support market expansion. Investment in clinical trials targeting safety and efficacy in vulnerable populations advances therapeutic options. Scale-up of manufacturing capacity and flexible supply chains improves access in diverse settings. Expansion of international aid programs enables distribution in low-resource regions. Growing focus on combination therapies and monoclonal antibodies broadens treatment portfolios and supports future innovation.Report Scope
The report analyzes the Mpox Therapeutics market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:- Segments: Treatment (Smallpox Vaccine, Antivirals, Vaccinia Immune Globulin); End-Use (Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)
- Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Smallpox Vaccine segment, which is expected to reach US$83.4 Million by 2032 with a CAGR of a 6.1%. The Antivirals segment is also set to grow at 9.7% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, valued at $24.5 Million in 2025, and China, forecasted to grow at an impressive 11.1% CAGR to reach $31.6 Million by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Mpox Therapeutics Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Mpox Therapeutics Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Mpox Therapeutics Market expected to evolve by 2032?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2032?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as Aegis Sciences Corporation, Bavarian Nordic A/S, Baxter International Inc., BioNTech SE, Chimerix Inc. and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Some of the companies featured in this Mpox Therapeutics market report include:
- Aegis Sciences Corporation
- Bavarian Nordic A/S
- Baxter International Inc.
- BioNTech SE
- Chimerix Inc.
- CIDIC Company Limited
- Emergent BioSolutions Inc.
- Emcure Pharmaceuticals Ltd.
- Gilead Sciences Inc.
- Hetero Drugs Limited
- Mylan N.V. (Viatris)
- Moderna Inc.
- Olon S.p.A.
- Piramal Enterprises Ltd.
- Pfizer Inc.
- Sanofi S.A.
- SIGA Technologies Inc.
- SymBio Pharmaceuticals Ltd.
- Teva Pharmaceutical Ltd.
- Tonix Pharmaceuticals
What Sets This Report Apart From Others?
- Grounded in Domain Expert Perspectives: Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.
- Captures Early Market Signals: Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.
- Draws From a Broad, Validated Intelligence Base: Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.
- Connects Signals With Strategic Market Direction: Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.
- Provides In-Depth Company Intelligence: Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.
- Market Share Is Examined Where It Matters: A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, the report extends market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISSOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
CANADA
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
ITALY
UNITED KINGDOM
SPAIN
RUSSIA
REST OF EUROPE
ASIA-PACIFIC
AUSTRALIA
INDIA
LATIN AMERICA
MIDDLE EAST
AFRICA
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Aegis Sciences Corporation
- Bavarian Nordic A/S
- Baxter International Inc.
- BioNTech SE
- Chimerix Inc.
- CIDIC Company Limited
- Emergent BioSolutions Inc.
- Emcure Pharmaceuticals Ltd.
- Gilead Sciences Inc.
- Hetero Drugs Limited
- Mylan N.V. (Viatris)
- Moderna Inc.
- Olon S.p.A.
- Piramal Enterprises Ltd.
- Pfizer Inc.
- Sanofi S.A.
- SIGA Technologies Inc.
- SymBio Pharmaceuticals Ltd.
- Teva Pharmaceutical Ltd.
- Tonix Pharmaceuticals
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 282 |
| Published | October 2026 |
| Forecast Period | 2025 - 2032 |
| Estimated Market Value ( USD | $ 90 Million |
| Forecasted Market Value ( USD | $ 148.6 Million |
| Compound Annual Growth Rate | 7.4% |
| Regions Covered | Global |
